‘We Have A Lot Of Work To Do,’ Says Head Of HIV + Hepatitis Policy Institute
CDC Puts Yearly Infections At 35,000
Executive Summary
Progress in reducing HIV infections has plateaued in the US. But with bipartisan support, federal funding and momentum in drug development there is reason for optimism, says HIV + Hepatitis Policy Institute executive director Carl Schmid.
You may also be interested in...
HIV Market To Meet Patent Cliff In 2026-27 But Novel Products Coming
Market Snapshot: Gilead’s Biktarvy and ViiV’s two-drug regimens are expected to dominate the HIV market over the next few years as market exclusivity losses loom, but drugs with new mechanisms of action, and longer-acting products, might influence market dynamics.
Biotech Foundations: Networks And Lab Space Are As Crucial As Funding
BioInnovation Institute chief business officer Bobby Soni shares how the life sciences incubator sources entrepreneurs and science globally, and the range of tools it provides to translate this into commercially viable companies.
Lithuania Caps Off Decade Of Growth With Stellar 2020
Lithuania’s life sciences sector has harnessed the country’s talent, infrastructure and government support to realize a decade of unprecedented growth. With the industry now maturing, can the Baltic state overcome challenges to become a significant European player?